Innovative image sensing technology for early diagnosis of diabetes and Alzheimer’s disease
The new biosensing technology consists of a semiconductor image sensor ( ‘charge coupled device’ developed by Toyohashi University of Technology) that is sensitive to extremely small changes in electric potential, and microbeads on which antigen-antibody reactions take place. This technology will enable monitoring and diagnosis of diseases for which specific markers are known using very small volumes of blood or urine. Specifically, this technology has detected amiloid beta-peptide, an agent responsible for Alzheimer’s disease.
Contracting a disease leads to expression of proteins specific to the diseases in the blood. This new technology is used for early diagnosis of diseases by using this specific protein as the antigen and a marker that captures the protein as the antibody and checking their antigen-antibody reaction. Conventional protocols used to monitor antibody-antigen reactions employ fluorescent probes and detection of fluorescence with microscopic cameras. This process is time consuming because of the necessity to measure fluorescence from the probes and cannot be used to detect low concentrations of antigens when the fluorescence intensity is too low to detect optically.
With this technology, a antigen-antibody reaction is used as in conventional methods, but fluorescence is not measured. Instead, this method employs a semiconductor image sensor to detect minute changes in electric potential generated during an antigen-antibody reaction.
Implementation of the technology will be tested for daily control of lifestyle diseases such as diabetes and in future the technology will be expanded for the early diagnosis of Alzheimer’s and Parkinson’ diseases.
Original publication
Other news from the department science
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.